CapsoVision (NASDAQ:CV) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded CapsoVision to a “hold” rating, bringing the consensus rating to “Hold” with an average analyst price target of $9.50. Ratings elsewhere range from “speculative buy” and “buy” to “sell.”
• CapsoVision shares opened at $5.87, below their 50-day and 200-day moving averages, while the company reported a quarterly loss of $0.15 per share on $3.64 million in revenue. Analysts expect a full-year loss of $0.56 per share.
• Insiders purchased 156,218 shares worth about $1.01 million over the past quarter, while institutional activity included BlackRock’s new position valued at approximately $14.4 million and State Street’s 340.7% position increase.

CapsoVision (NASDAQ:CV - Get Free Report) was upgraded by equities research analysts at Zacks Research to a "hold" rating in a research report issued on Monday, Zacks reports.

Other equities research analysts also recently issued reports about the stock. Benchmark reissued a "speculative buy" rating on shares of CapsoVision in a report on Friday, August 14th. Roth Capital initiated coverage on shares of CapsoVision in a report on Friday, August 28th. They set a "buy" rating and a $9.00 target price on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of CapsoVision in a report on Monday, June 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $9.50.

CapsoVision Trading Up 0.5%

CV stock opened at $5.87 on Monday. The stock's fifty day simple moving average is $6.55 and its two-hundred day simple moving average is $6.42. CapsoVision has a 1-year low of $3.43 and a 1-year high of $15.37. The stock has a market cap of $293.78 million, a P/E ratio of -12.49 and a beta of -2.47.

CapsoVision (NASDAQ:CV - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%.The company had revenue of $3.64 million for the quarter. As a group, analysts forecast that CapsoVision will post -0.56 earnings per share for the current fiscal year.

Insider Activity

In other CapsoVision news, major shareholder Eliyahou Et Al Harari purchased 61,068 shares of the stock in a transaction on Friday, July 17th. The stock was acquired at an average price of $6.73 per share, with a total value of $410,987.64. Following the transaction, the insider directly owned 3,343,119 shares of the company's stock, valued at approximately $22,499,190.87. This trade represents a 1.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders bought 156,218 shares of company stock valued at $1,007,902 over the last quarter. 2.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of CapsoVision during the second quarter valued at approximately $14,372,000. Bank of New York Mellon Corp purchased a new stake in shares of CapsoVision in the 2nd quarter worth approximately $569,000. State Street Corp increased its position in CapsoVision by 340.7% during the 4th quarter. State Street Corp now owns 85,929 shares of the company's stock valued at $919,000 after buying an additional 66,429 shares in the last quarter. Geode Capital Management LLC increased its position in CapsoVision by 34.1% during the 4th quarter. Geode Capital Management LLC now owns 154,264 shares of the company's stock valued at $1,649,000 after buying an additional 39,231 shares in the last quarter. Finally, Deutsche Bank AG purchased a new position in CapsoVision during the second quarter valued at $263,000.

CapsoVision Company Profile

CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source